Development of the hematopoetic prostaglandin D synthase inhibitor, GSK3350916A, for the treatment of Duchenne muscular dystrophy

GlaxoSmithKline

Non-confidential report

Name of applicant: Patrick Eidam

Reviewed: April, 2016 in Barcelona, Spain

6th TREAT-NMD Conference

9-11th December 2019

The aim of this international conference will be to share progress and lessons learned in the area of translational medicine in inherited neuromuscular diseases and plan for the delivery of future therapies to patients.

The conference will attract over 300 delegates including academics, patients and carers, patient advocacy organisations and clinical specialists.

Our last two conferences sold out, secure your place now at the very best early bird rate!

Register here!

Development of the hematopoetic prostaglandin D synthase inhibitor, GSK3350916A, for the treatment of Duchenne muscular dystrophy

GlaxoSmithKline

Sign up to our newsletter

6th TREAT-NMD Conference

Links

Contact us

TREAT-NMD

Recently Visited:

Development of the hematopoetic prostaglandin D synthase inhibitor, GSK3350916A, for the treatment of Duchenne muscular dystrophy

GlaxoSmithKline

Footer

Sign up to our newsletter

6th TREAT-NMD Conference

Links

Contact us

TREAT-NMD